Table 1 Clinical and demographic characteristics of 183 paclitaxel-treated patients
From: Polygenic risk of paclitaxel-induced peripheral neuropathy: a genome-wide association study
Clinical features | Median (IQR) or n (%) |
|---|---|
Age, years | 59 (18) |
Female | 179 (97.8%) |
BMI, kg/m2 | 26.0 (8.2) |
Time since treatment, months | 6 (7) |
Diabetes | 15 (8.2%) |
Cancer Type | |
 Breast | 103 (56.2%) |
 Ovarian | 42 (23%) |
 Endometrial | 25 (13.7%) |
 Other (Primary peritoneal serous papillary carcinoma, gastrointestinal, Testis, Larynx, Oesophagus, Cervical) | 13/183 (7.1%) |
Cancer Stage | |
 0/1 | 19 (10.4%) |
 2 | 58 (31.7%) |
 3 | 64 (35%) |
 4 | 26 (14.2%) |
 Unknown | 16 (8.7%) |
Paclitaxel treatment | |
 Cumulative paclitaxel dose, mg/m2 | 960 (240) |
 Ceased paclitaxel due to neurotoxicity | 45 (24.5%) |
 NCI-CTCAE grades |  |
 Grade 0 | 44 (24%) |
 Grade 1 | 74 (40.4%) |
 Grade 2 | 55 (30.1%) |
 Grades 3/4 | 10 (5.5%) |
 Neurological grading scale (TNSc) | 3 (4) |
 Patient reported CIPN (EORTC-QLQ-CIPN20) | 9.3 (15.8) |